This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rivier, G. Articles by Hughes, G. R.V. Search for Related Content PubMed PubMed Citation Articles by Rivier, G. Articles by Hughes, G. R.V. Social Bookmarking                   What's this?

Thrombosis and Antiphospholipid Syndrome: a Preliminary Assessment of Three Antithrombotic Treatments

Lupus Arthritis Research Unit, The Rayne Institute, St. Thomas' Hospital, London SE1 7EH, UK

M. Teresa Herranz

Lupus Arthritis Research Unit, The Rayne Institute, St. Thomas' Hospital, London SE1 7EH, UK

Munther A. Khamashta

Lupus Arthritis Research Unit, The Rayne Institute, St. Thomas' Hospital, London SE1 7EH, UK

Graham R.V. Hughes

Lupus Arthritis Research Unit, The Rayne Institute, St. Thomas' Hospital, London SE1 7EH, UK

To assess retrospectively three antithrombotic treatments in the secondary prevention of thrombosis in the antiphospholipid syndrome (APS), 23 patients (six systemic lupus erythematosus, seven lupus-like disease and 10 primary antiphospholipid syndrome) were included in this study. Treatments assessed were: (1) aspirin 75 mg daily, (2) warfarin (international normalised ratios (INRs) 2.0-2.9) ± aspirin 75 mg daily, and (3) warfarin (INRs > 2.9) ± aspirin 75 mg daily. Where patients had received two or three of these treatments successively, the periods of time on each treatment were added and the number of patients with recurrence(s) on each treatment were compared by Fisher's exact probability test.

'High' anticoagulation (INRs > 2.9) ± aspirin 75 mg daily was more effective than aspirin 75 mg daily in preventing further thromboembolic events (P = 0.0053). In addition, when comparing 'high' anticoagulation ± aspirin 75 mg daily versus 'low' anticoagulation (INRs 2.0-2.9) ± aspirin 75 mg daily, there was a trend in favour of 'high' anticoagulation (P = 0.066). No statistically significant difference could be demonstrated when comparing 'low' anticoagulation ± aspirin 75 mg daily with aspirin 75 mg daily (P = 0.092).

These results suggest that aggressive anticoagulation with or without low-dose aspirin is effective in preventing further thromboembolic events in APS.

Key Words: Anticardiolipin • Lupus • Anticoagulants

Lupus, Vol. 3, No. 2, 85-90 (1994)
DOI: 10.1177/096120339400300205


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				B. Tan, B. Thong, S Shivananda, W. Han, and H. Chng Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort Lupus, July 1, 2009; 18(8): 752 - 758. [Abstract] [PDF]

				G Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I M Gilboe, F Houssiau, T Huizinga, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics Ann Rheum Dis, February 1, 2008; 67(2): 195 - 205. [Abstract] [Full Text] [PDF]

				R. R. Leker and I. Steiner Anticardiolipin Antibodies Are Frequently Present in Patients With Idiopathic Intracranial Hypertension Arch Neurol, June 1, 1998; 55(6): 817 - 820. [Abstract] [Full Text] [PDF]

				L. Lakasing and L. Poston Adverse pregnancy outcome in the antiphospholipid syndrome: focus for future research Lupus, January 1, 1997; 6(9): 681 - 684. [Abstract] [PDF]

				F. Violi, D. Ferro, G. Valesini, S. I. Rapaport, D. T. Le, A. Slivka, E. Walz, A. J. Cole, S. Z. Nasr, A. L. Parke, et al. Thrombosis in the Antiphospholipid-Antibody Syndrome N. Engl. J. Med., September 7, 1995; 333(10): 665 - 667. [Full Text]

				M. A. Khamashta, M. J. Cuadrado, F. Mujic, N. A. Taub, B. J. Hunt, and G. R.V. Hughes The Management of Thrombosis in the Antiphospholipid-Antibody Syndrome N. Engl. J. Med., April 13, 1995; 332(15): 993 - 997. [Abstract] [Full Text] [PDF]

				P. Ames, M. Khamashta, and G. Hughes Clinical and therapeutic aspects of the antiphospholipid syndrome Lupus, July 1, 1994; 4(1_suppl): S23 - S25. [PDF]

				J.-C. Piette Prevention of Recurrent Thrombosis in the Antiphospholipid Syndrome Lupus, April 1, 1994; 3(2): 73 - 74. [PDF]